| Product to be launched as Absorica™ In the U.S. Market in Q4 2012 PRINCETON, N.J., May 29, 2012 /PRNewswire/ -- Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica™, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne. Through a business agreement with the Canadian firm, Ciph...continued CPHMF DND:CA Healthcare Drugs |
Tuesday, May 29, 2012
Ranbaxy Announces U.S. FDA Approval of CIP-Isotretinoin NDA
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment